KEY POINTS
1. Brain derived cellular microparticles induce systemic coagulopathy in traumatic brain injury.
2.
Platelets facilitate the transmigration of brain microparticles through the endothelial barrier into the circulation.
For personal use only. on August 13, 2017 . by guest www.bloodjournal.org From ABSTRACT: Traumatic brain injury (TBI) is associated with coagulopathy, although it often lacks two key risk factors: severe bleeding and significant fluid resuscitation associated with hemorrhagic shock. The pathogenesis of TBI-associated coagulopathy remains poorly understood. We tested the hypothesis that brain-derived microparticles (BDMPs) released from an injured brain induce a hypercoagulable state that rapidly turns into consumptive coagulopathy. Here, we report that mice subjected to fluid percussion injury (1.9±0.1 atm) developed a BDMP-dependent hypercoagulable state, with peak levels of plasma glial cell and neuronal BDMPs reaching 17,496 ± 4,833/μl and 18,388 ± 3,657/μl, respectively, 3 hrs post TBI. Uninjured mice injected with BDMPs developed a dose-dependent hyper-turned hypo-coagulable state measured by a progressively prolonged clotting time, fibrinogen depletion, and microvascular fibrin deposition in multiple organs. The BDMPs were measured 50 -300 nm with intact membranes, expressing neuronal or glial cell markers and procoagulant phosphatidylserine and tissue factor. Their procoagulant activity was greater than platelet microparticles and was dose-dependently blocked by lactadherin. Microparticles were produced from injured hippocampal cells, transmigrated through the disrupted endothelial barrier in a platelet-dependent manner, and activated platelets. These data define a novel mechanism of TBI-associated coagulopathy in mice, identify early predictive markers and provide alternative therapeutic targets.
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INTRODUCTION
Uncontrolled hemorrhage is a leading cause of the preventable deaths that occur in patients with trauma, accounting for 30-40% of all trauma fatalities.
1;2 It is caused by direct injury to the vasculature and a resulting secondary coagulopathy. The causes of trauma-associated coagulopathy include blood loss, consumption of coagulation factors and platelets, the dilution of coagulation factors and platelets due to fluid resuscitation, and hypothermia. 3;4 Recent studies also implicate a role of activated protein C in the coagulopathy associated with severe trauma 5;6 Retrospective and observational studies have consistently shown that coagulopathy is common in patients with traumatic brain injury (TBI). [7] [8] [9] [10] [11] However, isolated TBI lacks two key causal factors for coagulopathy associated with injury to the trunk and limbs: heavy blood loss and a large volume of fluid resuscitation, suggesting that it follows a distinct pathogenic pathway. The finding that coagulopathy is common in patients with penetrating brain injury 10 further indicates that damage to cerebral tissue plays a role in developing the coagulopathy. In a study of 972 TBI patients with coagulopathy, D-dimer and fibrinogen degradation products were detected minutes after injury, followed by a profound depletion of fibrinogen. 8 Prolonged prothrombin and partial thromboplastin times usually occurred late, indicating a transition from a hyper-to a hypo-coagulable state. 8;9 Despite strong clinical and laboratory evidence of its presence and association with poor clinical outcomes, 12 the pathogenesis of TBI-associated coagulopathy remains
For personal use only. on August 13, 2017 . by guest www.bloodjournal.org From poorly understood. Current clinical tests detect the coagulopathy, but are insufficient to determine its causes or to predict its occurrence, making clinical management of TBIassociated coagulopathy difficult and costly. We hypothesized that brain-derived procoagulant molecules delivered in the form of cellular microparticles play a role in developing systemic coagulopathy after TBI. This hypothesis is derived from several observations. First, the brain is enriched in procoagulant anionic phospholipids, such as phosphatidylserine (PS), which provide a negatively charged surface to initiate and propagate coagulation. 13 These anionic phospholipids are normally present on the inner leaflet, 14 whereas neutral phospholipids, such as phosphatidylcholine (PC) and sphingomyelin, are on the external leaflet of the cell membrane. 15 This asymmetry is lost in cells subjected to traumatic and/or ischemic injuries, exposing PS on the outer membrane. 16 Second, tissue factor (TF), which initiates the extrinsic pathway of coagulation on platelets, is also richly expressed on neurons and glial cells. [17] [18] [19] A longstanding question is how TF and PS are integrated into the membrane of activated platelets, which express no or an extremely low level of TF, 20;21 in order to initiate the coagulation during trauma hemostasis. One potential mediator is cellular microparticles.
Microparticles are cell fragments produced from activated or apoptotic cells. 22;23 They are primarily composed of the plasma membrane along with a limited amount of cytoplasm and measure 0.1 to 1 μm in diameter. 23 
MATERIALS AND METHODS

A mouse model of FPI
Adult male C57BL/6J mice (12-16 wks and 22-25g, Jackson Laboratory, Bar Harbor, ME) were subjected to fluid percussion injury (FPI). 33 Briefly, a mouse was anesthetized by ketamine and xylazine (1 mg and 0.1 mg/10g) on a ventilator (Harvard Apparatus, Hollistone, MA) and constrained to a platform to surgically expose the skull. A 3-mm diameter hole was drilled into the skull (2.0-mm posterior from the bregma and 2.0-mm lateral to the sagittal suture) with the dura matter intact. A female Leur-Lok was cemented to the craniotomy site of the mouse that had been allowed to recover from the surgery for 60 min and was connected to an FPI device (Custom Design & Fabrication,
Richmond, VA). With the head unrestrained, saline from a Plexiglas cylindrical reservoir was rapidly injected into the closed cranial cavity at a controlled pressure of 1.9 ± 0.1 atm. A sham mouse underwent the same surgery without being exposed to FPI. To model the acute events and to minimize impacts of secondary injury, all mice were examined within the first 6 hrs after FPI. The mouse study is approved by the IACUC of PSBC.
Detection of brain-derived microparticles
Neuron-and glial cell-derived microparticles (collectively termed BDMP) were identified by a modified flow cytometry-based method (Fig. S1 ). 34 They were first identified by their size (< 1 μm) using standard microbeads that were 0.5, 0.9, and 3 μm in diameter (Biocytex, Marseille, France) and then by their expression of neuron specific enolase (NSE) and glial fibrillary acidic protein (GFAP) using FITC-conjugated monoclonal The expression of TF and PS on BDMPs were detected using a PE-conjugated polyclonal antibody (Bioss, Inc., Woburn, MA) and APC-conjugated Annexin V (eBioscience), respectively. EDTA (5 mM) was used to test the specificity of this assay (Fig. S2 ). BDMPs were quantified by double-labeling with antibodies to GFAP/NSE and annexin V binding.
Coagulation assays
Two coagulation assays were performed to evaluate BDMP-associated procoagulant activity in order to assess relative contributions of PS and TF. The first was a PSdependent assay that tested the ability of BDMPs to promote clot formation in the presence of coagulation factor Xa. 37 For each reaction, 25 μl of phosphate-buffered saline (PBS) containing a known number of BDMPs were mixed with 25 μl of (Fig. S4 ).
Effects of BDMPs on platelets
Human blood samples were collected in 0.38% sodium citrate from healthy subjects under an approved IRB protocol. They were centrifuged at 150 x g for 15 min at Scanning electron microscopy was also utilized to observe the BDMP-platelet interaction (supplemental method).
42
Statistical analysis
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Categorical (frequency) variables were expressed as percentages and continuous variables as the mean ± SEM. Data were analyzed using Sigma plot (V. 11.2) for the paired t-test, one way or repeated measures ANOVA as specified in each dataset. A p value of less than 0.05 was considered to be statistically significant.
RESULTS
Development of a BDMP-dependent hyper-coagulable state in TBI mice
At a mean fluid pressure of 1.9 ± 0.1 atm generated from a FPI device, mice sustained cerebral injury visible at the site of impact (Fig. 1A) . When measured by a PSdependent clotting assay, plasma from TBI mice had a significantly shortened (accelerated) clotting time compared to plasma from mice with sham surgery (Fig. 1B) .
This shortened clotting time was reversed when microparticles were removed from the plasma (Fig. 1C) . In parallel with changes in the clotting time, glial cell-(GFAP + ) and neuron-derived (NSE + ) BDMPs were detected in blood samples from the TBI mice ( respectively. The numbers of BDMPs at other time points were calculated by extrapolating values at peak levels 3 hrs post TBI (Fig. S6 ) and found to be consistent.
The level of plasma GFAP + microparticles decreased 6 hrs post-injury, whereas NSE + microparticles remained relatively constant. A portion of these BDMPs expressed PS as detected by annexin V (Fig. 1F) . The percent of PS + BDMPs varied considerably among individual mice, accounting for 39 ± 21% and 42 ± 26% of total GFAP + and NSE + microparticles, respectively.
For
BDMPs were also detected in blood samples from mice that had undergone sham surgery ( Fig. 1D & E) , but reaching peak levels of 1,853 ± 745/μl (GFAP + ) and 2,153 ± 889/μl (NSE + ), significantly lower than those found in TBI mice (n = 12, p < 0.01).
Procoagulant activity of BDMPs
Specifically investigating the role of BDMPs in the development of TBI-associated coagulopathy is challenging in mice with FPI, because microparticles from endothelial and blood cells are also released in response to traumatic stress. To overcome this technical challenge, we generated BDMPs from the brains of adult C57BL/6J mice by freeze-thawing injury. 37 The BDMPs thus produced resemble those detected in the plasma of FPI mice in size and levels of PS and GFAP expression (Fig. S7 ). When viewed under transmission electron microscopy, these BDMPs were irregular spheres of 50-500 nm in diameter, with a clearly defined and relatively intact membrane, but without apparent granules ( Fig. 2A) . They expressed NSE and GFAP (Fig. 2B ) and could be classified as TF + , PS + , and TF + /PS + microparticles (Fig. 2C) . In contrast, we did not detect VWF (Fig. 2B) , a common marker for Weibel-Palade bodies of endothelial cells and α-granules of platelets that overlap in size (~50-200 nm) and could be copurified along with BDMPs. The surface markers for leukocytes (CD45), endothelial cells (CD144), and erythrocytes (CD235a) were also negative (Fig. S8) , suggesting that the contaminants from blood and endothelial cells were below the detection in these BDMP preparations.
For personal use only. on August 13, 2017. by guest www.bloodjournal.org From When added to phospholipid-free plasma, BDMPs accelerated the rate of PSdependent clot formation in a dose-dependent manner, reaching a maximal activity at ~1 x 10 5 BDMPs/μl, which was equivalent to 1.6 μg/μl of purified brain PS (Fig. 2D ).
This PS-dependent procoagulant activity was blocked by the PS-binding protein lactadherin (Fig. 2E) , which bound BDMPs (Fig. S9) . The BDMP-lactadherin interaction was partially blocked by purified PS, but not PC (Fig. S10) . In comparable numbers, BDMPs were significantly more active in promoting clot formation than the microparticles generated from platelets activated by collagen, which is known to induce platelet microvesiculation (supplemental method, Fig. S11 ). 43 These platelet microparticles expressed PS, but not TF at a detectable level (Fig. S12 ). BDMPs also promoted thrombin generation in a TF-dependent assay, where 25,000/μl of BDMPs had an activity equivalent to 1 pM of soluble TF (Fig. 2E ). This BDMP-induced thrombin generation had a significantly delayed onset and a smaller AUC (Tab. 1). In both assays, the number of BDMPs that induced a maximal level of coagulation ( Fig. 2D & E) was comparable to that detected in FPI mice ( Fig. 1D & E) .
To specifically measure the procoagulant activity of BDMPs in vivo, we injected BDMPs into uninjured mice through the tail vein and collected blood samples 30 min after injection to measure the rate of clot formation and the level of plasma fibrinogen. The lungs, kidney, and heart were also collected at the same time and evaluated for fibrin deposition, a hallmark of consumptive coagulopathy. In this experimental setting, mice injected with 1 x 10 4 /μl of BDMPs showed a tendency toward a shortened clotting time.
Further increases in the number of BDMPs resulted in a progressively prolonged
For personal use only. on August 13, 2017. by guest www.bloodjournal.org From clotting time (Fig. 3A) . Consistent with this dose-dependent biphasic hyper-turned hypocoagulable state, the plasma level of fibrinogen was progressively reduced by an increasing number of BDMPs injected (Fig. 3B) . Phosphotungstic acide hematoxylin stain (PTAH) revealed a wide-spread fibrin deposition in the microvasculature of the lungs, kidney, and heart of the mice injected with BDMPs, but not in the same organs of mice injected with PBS ( Fig. 3C-H) . These data show that BDMPs induced a dosedependent transition from a hyper-coagulable state to consumptive coagulopathy, consistent with the phenotype observed in TBI mice and patients with TBI.
BDMP production by injured brain cells and transmigration through the disrupted endothelial barrier
The data have so far shown that injured brain released BDMPs into the systemic circulation through the traumatized blood-brain barrier (BBB), resulting in intravascular coagulation. The extravasation of Evans blue was indeed observed in brains dissected from mice with FPI, but not from those with sham surgery (Fig. 4A) . The production and transmigration of BDMPs were further examined in vitro. Cultured hippocampal cells (Fig. 4B ) released microparticles after stimulation with the calcium ionophore A23187 (Fig. 4C) , an agent known to induce apoptosis and microvesiculation. 44 The ability of BDMPs to pass through the endothelial barrier was measured in a transwell system, where confluent human umbilical cord endothelial cells (HUVECs) cultured in the top chamber were first activated by histamine (Fig. 4D) (Fig. 1 ), BDMPs were detected in the bottom chamber when they were incubated with histamine-stimulated HUVECs and live, but not lyophilized platelets (Fig. 4E) . Live platelets also facilitated a lower rate of BDMP transmigration through unstimulated HUVECs. To further examine a role of platelets in promoting BDMP transmigrantion, we tested serotonin, a major component of platelet dense granules that is released upon platelet activation 47 and is known to enhance the procoagulant properties of platelets 48 and to increase vascular permeability. 49 As shown in Fig. 4E , serotonin at 5 μM promoted the transmigration of BDMPs through the endothelial barrier at a level similar to that induced by live platelets on histamine-stimulated HUVECs.
A role of platelets in assisting the transmigration of BDMPs through activated HUVECs was further examined by SEM that detected BDMPs on the transwell membrane in the opposite side of histamine-activated HUVECs incubated with BDMPs with, but not without platelets (Fig. 4F) .
Effects of BDMPs on platelets
The data presented in Figure 4E & 4F suggest that platelets assisted the transmigration of BDMP through a disrupted endothelial barrier. Therefore, we examined if this platelet-BDMP interaction affected platelet function. BDMPs were detected binding platelets by flow cytometry (Fig. 5A ) and scanning electron microscopy (Fig. 5B) . Furthermore, BDMPs induced rapid and time-dependent calcium influx in platelets that reached a plateau 15 min after the stimulation (Fig. 5C ). Platelets incubated with BDMPs also
For personal use only. on August 13, 2017 . by guest www.bloodjournal.org From expressed CD62p (Fig. 5D) and PS (Fig. 5E ). In contrast, BDMPs did not directly induce platelet aggregation or enhance collagen-induced platelet aggregation (Fig. 5F ).
DISCUSSION
Acute changes in coagulation associated with TBI were studied using a mouse FPI model combined with reciprocal mouse and complementary in vitro experiments to identify their causes. We focused on the early hours post TBI (≤ 6 hrs) in order to minimize confounding changes induced by secondary events, such as ischemic injury.
We made several novel observations that define a causal role for BDMPs in the systemic coagulation associated with TBI in mouse models.
First, mice subjected to FPI developed a hypercoagulable state within 3 hrs of the injury and this hypercoagulable state was reversed when microparticles were removed (Fig. 1) .
The development of this hypercoagulable state was associated in time with BDMPs reaching peak levels in the circulation. Although widely used as a neuronal marker, NSE is also detected in human serum, platelets and erythrocytes. 35;36;50 We presented several lines of experimental evidence to the brain origin of these MPs: 1) validation of BDMPs with a second set of neuronal and glial cell markers (Fig. S5 ) and 90-98% of BDMPs stained positive for both sets of markers; 2) detection of MPs that are positive for GFAP, a much more specific marker for glial cells (Fig. 1E) , and 3) identical flow cytometric profiles of BDMPs from TBI mice and those made from mouse brain (Fig. S7) .
Interestingly, we did not detect NSE in mouse platelet microparticles (Fig. 2B) ,
suggesting that NSE in platelets may not be microparticle-bound.
In reciprocal experiments, uninjured mice injected with BDMPs underwent a rapid and dose-dependent transition from a hyper-coagulable state to a consumptive (Fig. 3) , as demonstrated by 1) a transition from mildly shortened to significantly prolonged clotting time, 2) a progressive reduction (depletion) of plasma fibrinogen with increasing dosing of BDMPs, and 3) widespread fibrin deposition in the vasculature. The observation that mice subjected to FPI developed a clearly defined hypercoagulable state, whereas coagulopathy rapidly occurred in mice injected with a similar number of BDMPs proceeded with a mild hypercoagulable state (Fig. 1 vs. Fig.   3 ), suggests that the speed of BDMP release into the circulation is critical for the development of coagulopathy. BDMPs were released over time from a traumatically injured brain, but injected as a bolus (< 5 min) into an uninjured mouse.
The procoagulant activity of BDMPs requires PS and TF on the surface of these microparticles because it was 1) detected in both PS-dependent and TF-dependent coagulation assays (Fig. 2) , 2) dose-dependently blocked by the PS-binding protein, lactadherin (Fig. 2) , and 3) greater than a comparable number of platelet microparticles that did not have a detectable level of TF (Fig. S4) . BDMP-facilitated thrombin generation had a delayed onset and smaller AUC compared to soluble human TF (Fig.   2 & Tab. 1) . The distinct kinetics may result from: 1) cooperativity between TF and PS co-expressed on BDMPs, as compared to soluble TF and PS added separately, 2) structural and functional differences between membrane-bound and soluble TF, and/or 3) species differences between BDMP-bound mouse TF and soluble human TF.
Another critical observation is that BDMPs were detected (albeit at a very low level) in mice exposed to sham surgery (Fig. 1) , likely due to minor injury associated with the For personal use only. on August 13, 2017 . by guest www.bloodjournal.org From surgery. The finding suggests that brain cells are highly sensitive to microvesiculation.
This residual level of BDMPs had a minimal influence on coagulation in the acute stage of injury (Fig. 1) , but its long-term impacts, especially after repeated exposures, remains to be determined.
Second, we have demonstrated that BDMPs activate platelets (Fig. 5) . Platelets may facilitate the transmigration of BDMPs through a disrupted endothelial barrier (Fig. 4 ) by serving as a carrier or by promoting local inflammation at a site of vascular injury. The former is unlikely because the membrane pores used in the culture matrix of the transwell were 0.4 μm in diameter, substantially smaller than activated platelets (5-7 μm) and lyophilized platelets failed to support the transmigration (Fig. 4E) . In the latter case, BDMP-activated platelets release pro-inflammatory mediators that can induce or propagate local inflammation. One of such mediators may be serotoin as it has been previously reported to increase vascular permeability. 51 This inflammatory activity may explain why live, but not lyophilized platelets, promoted BDMP transmigration through unstimulated endothelial cells. Surprisingly, BDMPs did not directly induce platelet aggregation or enhance its induction by collagen, potentially due to the steric hindrance of BDMPs that prevents platelet-to-platelet contacts.
Third, we demonstrated the ability of lactadherin to block PS-dependent procoagulant activity (Fig. 2E) , raising two important perspectives. The first is that PS scavengers and PS-neutralizing molecules, such as lactadherin and annexin V, may reduce TBIassociated coagulopathy and BDMP-induced platelet activation. Annexin V has been
For personal use only. on August 13, 2017 . by guest www.bloodjournal.org From reported to inhibit arterial thrombosis in a rabbit model of carotid artery injury. 52 The second is that an intrinsic or acquired deficiency in a PS-dependent clearance of cancer-associated thrombosis. 53 Our results further suggest that microparticles from injured tissues/organs contribute to trauma-associated coagulopathy. 
-test).
